Liquiritigenin inhibits amyloid β-peptide-induced neurotozicity，the secretion of amyloid β-peptide as well as fibril formation in vitro
Background and Purpose: Amyloid β-peptide(AP) is a pivotal pathological factor in Alzheimer”s disease(AD). Estrogen is beneficial to patients with AD but its proliferation and oncogenic effects on non-neuronal cells has dampened the enthusiasm forthe use of estrogen in clinic. In an attempt to find estrogen substitutes that retain the beneficial effects of estrogen with minimal side effects，we have screened liquirigenin as a highly selective estrogen receptor β(Erβ) agonist. Considering estrogen has well established neuroprotection actions，in the present study，we examined the neuroprotective activities of liquiritigenin on Aβ(25-35)-induced damage and we analyzed actions of liquiritigenin on the secretion of Aβ(1-40) in a human neuroblastoma SH-SY5Y cell line. Then，we have externled our studies by testing whether liquiritigenin can inhibit fibrilformation. Finally，the related genes and protein were examined.
liquiritegenin selectiveERβagonist neuroprotective Aβsecretion fibilformation
Ruiting Liu Guangxing Bian Libo Zou Qiujun Lu
Institute of Radiation Medicine，Academy of Military Medical Science，Beijing，100850，China; School of Institute of Radiation Medicine，Academy of Military Medical Science，Beijing，100850，China School of Life Science and Biological Pharmacy,Shenyang Pharmaceutical University,China Institute of Radiation Medicine，Academy of Military Medical Science，Beijing，100850，China;Tel: 010-66
国内会议
大连
英文
40-41
2008-09-19（万方平台首次上网日期，不代表论文的发表时间）